UCB is a 5,000+ person biopharmaceutical manufacturer headquartered in Brussels with operations across nearly 40 countries, focused on central nervous system and immunological conditions. The tech stack reveals a company mid-transformation: SAP S/4HANA, Veeva (CRM and Engage), and MES/SCADA adoption signal modernization of manufacturing and commercial infrastructure, while simultaneous investment in data analytics (Power BI, Qlik Sense, SAS, R) and real-world evidence projects indicates a shift toward outcomes-driven product positioning. Sales and manufacturing hiring (78 and 58 open roles respectively) outpace engineering (43), pointing to commercial execution and supply-chain scale as near-term priorities.
Notable leadership hires: Digital Technology Lead, Complaint Escalation Lead, Digital Transformation Lead, Evidence Generation Lead, Customer Engagement Lead
UCB develops and manufactures biopharmaceutical treatments for severe neurological and immunological diseases. The company operates a global commercial and manufacturing footprint spanning over 35 countries, with significant hiring activity in Belgium, the United States, Japan, Germany, the United Kingdom, and across Asia, Europe, and the Americas. Core operations include clinical development, manufacturing and technology transfer, managed access programs, and regulatory compliance—supported by a diverse tech infrastructure spanning ERP (SAP), CRM (Salesforce, Veeva), lab and quality systems (LIMS, HPLC, UPLC), and data analytics platforms. Active projects center on new product launches, real-world evidence generation, digital transformation of manufacturing processes, and inspection readiness—with persistent focus on data quality, regulatory compliance, and patient access barriers.
UCB runs SAP (S/4HANA, PM, MM) for ERP, Salesforce (Health Cloud, Service Cloud) and Veeva (CRM, Engage) for commercial operations, MES/SCADA for manufacturing, LIMS/HPLC/UPLC for lab operations, and Power BI/Qlik Sense/SAS/R for analytics. Also uses Azure, SharePoint, and specialized pharma standards (CDISC SDTM/ADaM).
Active projects include new product launches, real-world evidence (RWE) programs, digital process transformation, managed access program strategy, technology transfer for manufacturing, equipment qualification, and inspection readiness initiatives. Recurring pain points center on data quality, regulatory compliance, and improving patient access.
Other companies in the same industry, closest in size